Unknown

Dataset Information

0

Estrogen receptor beta as a novel target of androgen receptor action in breast cancer cell lines.


ABSTRACT: INTRODUCTION: The two isoforms of estrogen receptor (ER) alpha and beta play opposite roles in regulating proliferation and differentiation of breast cancers, with ER-alpha mediating mitogenic effects and ER-beta acting as a tumor suppressor. Emerging data have reported that androgen receptor (AR) activation inhibits ER-positive breast cancer progression mainly by antagonizing ER-alpha signaling. However, to date no studies have specifically evaluated a potential involvement of ER-beta in the inhibitory effects of androgens. METHODS: ER-beta expression was examined in human breast cancer cell lines using real-time PCR, Western blotting and small interfering RNA (siRNA) assays. Mutagenesis studies, electromobility shift assay (EMSA) and chromatin immunoprecipitation (ChIP) analysis were performed to assess the effects of mibolerone/AR on ER-beta promoter activity and binding. RESULTS: In this study, we demonstrate that mibolerone, a synthetic androgen ligand, up-regulates ER-beta mRNA and protein levels in ER-positive breast cancer cells. Transient transfection experiments, using a vector containing the human ER-beta promoter region, show that mibolerone increases basal ER-beta promoter activity. Site-directed mutagenesis and deletion analysis reveal that an androgen response element (ARE), TGTTCT motif located at positions -383 and -377, is critical for mibolerone-induced ER-beta up-regulation in breast cancer cells. This occurs through an increased recruitment of AR to the ARE site within the ER-beta promoter region, along with an enhanced occupancy of RNA polymerase II. Finally, silencing of ER-beta gene expression by RNA interference is able to partially reverse the effects of mibolerone on cell proliferation, p21 and cyclin D1 expression. CONCLUSIONS: Collectively, these data provide evidence for a novel mechanism by which activated AR, through an up-regulation of ER-beta gene expression, inhibits breast cancer cell growth.

SUBMITTER: Rizza P 

PROVIDER: S-EPMC3978907 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature

altmetric image

Publications

Estrogen receptor beta as a novel target of androgen receptor action in breast cancer cell lines.

Rizza Pietro P   Barone Ines I   Zito Domenico D   Giordano Francesca F   Lanzino Marilena M   De Amicis Francesca F   Mauro Loredana L   Sisci Diego D   Catalano Stefania S   Dahlman Wright Karin K   Gustafsson Jan-Ake JA   Andò Sebastiano S  

Breast cancer research : BCR 20140219 1


<h4>Introduction</h4>The two isoforms of estrogen receptor (ER) alpha and beta play opposite roles in regulating proliferation and differentiation of breast cancers, with ER-alpha mediating mitogenic effects and ER-beta acting as a tumor suppressor. Emerging data have reported that androgen receptor (AR) activation inhibits ER-positive breast cancer progression mainly by antagonizing ER-alpha signaling. However, to date no studies have specifically evaluated a potential involvement of ER-beta in  ...[more]

Similar Datasets

| S-EPMC3180861 | biostudies-literature
| S-EPMC3039394 | biostudies-literature
| S-EPMC5731994 | biostudies-literature
| S-EPMC8008732 | biostudies-literature
| S-EPMC3505272 | biostudies-literature
| S-EPMC4744541 | biostudies-literature
| S-EPMC5187506 | biostudies-literature